Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients

Arulananda, Surein; Liew, Mun Sem; Wada, M.; Cher, Lawrence; Gan, Hui

doi:10.1111/imj.14000

Cited by 7 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A platelet count below 50 × 10 9 /L can trigger mucosal or cutaneous hemorrhages, resulting in spontaneous bleeding as the platelet count continues to decline [ 11 , 12 ]. At present, the pathogenesis of thrombocytopenia has not been fully clarified and most scholars believe that it is caused by excessive T cell-mediated platelet destruction, impaired megakaryocytopoiesis, and thrombopoiesis and a disturbed T-helper-cell (Th) balance [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

Wang

Shao

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Even though cytopenia caused by either chemotherapy or radiotherapy is a common complication in cancer patients, chemoradiotherapy remains an essential treatment for the majority of patients. The purpose of this study was to look into the clinical efficacy and cost-effectiveness of recombinant human thrombopoietin (rhTPO) in treating chemo- or chemoradiotherapy-induced grade II, III, and IV thrombocytopenia. From December 2019 to November 2020, 233 lung cancer patients admitted to our hospital with chemotherapy- or chemoradiotherapy-induced thrombocytopenia were enrolled and treated with rhTPO. The study's findings revealed a significant disparity in the use of concurrent chemoradiotherapy in patients with grade II, III, and IV thrombocytopenia. All costs, including rhTPO treatment costs, platelet costs, drug costs, and nondrug costs, tended to rise as the severity of thrombocytopenia increased. In the treatment of chemotherapy or radiotherapy-induced thrombocytopenia, rhTPO has shown good clinical efficacy. In the treatment of grade II thrombocytopenia, rhTPO has a favorable economic evaluation. As a result, early intervention and thrombocytopenia treatment should be provided, which warrants further clinical investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

Wang

Shao

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)

et al. 2021

View full text Add to dashboard Cite

Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study

et al. 2022

View full text Add to dashboard Cite

Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients

Abstract: Our toxicity data were within range of the literature. We identified the group of patients that have increased thrombocytopenia risk. Larger pooled retrospective series and prospective studies are required.

Cited by 7 publications

References 10 publications

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)

Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study

Contact Info

Product

Resources

About